1
|
de Maat GE, Mulder BA, Van de Lande ME, Rama RS, Rienstra M, Mariani MA, Maass AH, Klinkenberg TJ. Long-Term Performance of Epicardial versus Transvenous Left Ventricular Leads for Cardiac Resynchronization Therapy. J Clin Med 2023; 12:5766. [PMID: 37762709 PMCID: PMC10531585 DOI: 10.3390/jcm12185766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2023] [Revised: 08/20/2023] [Accepted: 08/31/2023] [Indexed: 09/29/2023] Open
Abstract
Aims: to study the technical performance of epicardial left ventricular (LV) leads placed via video assisted thoracic surgery (VATS), compared to transvenously placed leads for cardiac resynchronization therapy (CRT). Methods: From 2001 until 2013, a total of 644 lead placement procedures were performed for CRT. In the case of unsuccessful transvenous LV lead placement, the patient received an epicardial LV lead. Study groups consist of 578 patients with a transvenous LV lead and 66 with an epicardial LV lead. The primary endpoint was LV-lead failure necessitating a replacement or deactivation. The secondary endpoint was energy consumption. Results: The mean follow up was 5.9 years (epicardial: 5.5 ± 3.1, transvenous: 5.9 ± 3.5). Transvenous leads failed significantly more frequently than epicardial leads with a total of 66 (11%) in the transvenous leads group vs. 2 (3%) in the epicardial lead group (p = 0.037). Lead energy consumption was not significantly different between groups. Conclusions: Epicardial lead placement is feasible, safe and shows excellent long-term performance compared to transvenous leads. Epicardial lead placement should be considered when primary transvenous lead placement fails or as a primary lead placement strategy in challenging cases.
Collapse
Affiliation(s)
- Gijs E. de Maat
- Department of Cardio-Thoracic Surgery, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (G.E.d.M.); (M.A.M.); (T.J.K.)
| | - Bart A. Mulder
- Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (B.A.M.); (M.E.V.d.L.); (R.S.R.); (M.R.)
| | - Martijn E. Van de Lande
- Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (B.A.M.); (M.E.V.d.L.); (R.S.R.); (M.R.)
| | - Rajiv S. Rama
- Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (B.A.M.); (M.E.V.d.L.); (R.S.R.); (M.R.)
| | - Michiel Rienstra
- Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (B.A.M.); (M.E.V.d.L.); (R.S.R.); (M.R.)
| | - Massimo A. Mariani
- Department of Cardio-Thoracic Surgery, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (G.E.d.M.); (M.A.M.); (T.J.K.)
| | - Alexander H. Maass
- Department of Cardiology, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (B.A.M.); (M.E.V.d.L.); (R.S.R.); (M.R.)
| | - Theo J. Klinkenberg
- Department of Cardio-Thoracic Surgery, University Medical Center Groningen, P.O. Box 30.001, 9700 RB Groningen, The Netherlands; (G.E.d.M.); (M.A.M.); (T.J.K.)
| |
Collapse
|
2
|
Koike T, Shoda M, Ejima K, Yagishita D, Suzuki A, Hasegawa S, Kataoka S, Yazaki K, Higuchi S, Kanai M, Yamaguchi J. Impact of
fracture‐prone
implantable cardioverter defibrillator leads on
long‐term
patient mortality. J Arrhythm 2023. [DOI: 10.1002/joa3.12843] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023] Open
|
3
|
Giacopelli D, Azzolina D, Comoretto RI, Quartieri F, Rovaris G, Schillaci V, Gargaro A, Gregori D. Implantable cardioverter defibrillator lead performance: A systematic review and individual patient data Meta-analysis. Int J Cardiol 2023; 373:57-63. [PMID: 36460209 DOI: 10.1016/j.ijcard.2022.11.048] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/04/2022] [Revised: 11/07/2022] [Accepted: 11/24/2022] [Indexed: 11/30/2022]
Abstract
BACKGROUND Reliable post-approval surveillance of implantable cardioverter-defibrillator (ICD) lead performance remains a challenge. In the past, two ICD leads were recalled due to a high frequency of failures. In this meta-analysis, we sought to provide a combined estimate of failure-free rate for ICD leads by reconstructing individual patient data from published Kaplan-Meier (KM) curves and to investigate whether estimates could be influenced by the characteristics of the study. METHODS Observational studies assessing failure-free estimates of transvenous ICD leads with KM method, were identified through a systematic search up to November 2021. RESULTS Forty-four studies were eligible that included 41,870 (63.1%) non-recalled leads and 24,493 (36.9%) recalled leads. The 8-year cumulative failure-free rate was 94.1% (CI, 93.6% - 94.6%) for contemporary non-recalled leads and 81.2% (80.3% - 82.0%) for recalled leads (hazard ratio [HR], 3.15 [2.85-3.47], p < 0.001). Failure-free rate was lower in single-center studies in both the non-recalled (HR, 0.28 [0.15-0.51], p < 0.001) and recalled (HR, 0.54 [0.33-0.88], p = 0.014) group compared with multicenter studies. Similarly, estimates were significantly lower in small (i.e. extracted KM curve with <312 leads) versus large studies (HR non-recalled group, 0.54 [CI, 0.33-0.89], p = 0.015; HR recalled group, 0.62 [CI, 0.43-0.89], p = 0.009). CONCLUSIONS In this meta-analysis including >66,000 leads, we provide pooled survival curves that may play a role in generating evidence-based standards for assessing clinically acceptable failure rates for ICD leads. Lead performance was underestimated with single-center and small-sized studies; multicenter studies remain the main tool to reliably conduct post-market surveillance of ICD leads.
Collapse
Affiliation(s)
- Daniele Giacopelli
- Department of Cardiac, Thoracic, Vascular Sciences & Public Health, University of Padova, Padova, Italy; Clinical Unit, Biotronik Italia, Milan, Italy.
| | - Danila Azzolina
- Department of Environmental and Preventive Sciences, University of Ferrara, Ferrara, Italy
| | | | - Fabio Quartieri
- Department of Cardiology, Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | | | | | | | - Dario Gregori
- Department of Cardiac, Thoracic, Vascular Sciences & Public Health, University of Padova, Padova, Italy
| |
Collapse
|
4
|
Frey SM, Sticherling C, Altmann D, Brenner R, Kühne M, Ammann P, Coslovsky M, Osswald S, Schaer B. The Medtronic Sprint Fidelis® lead history revisited-Extended follow-up of passive leads. Pacing Clin Electrophysiol 2019; 42:1529-1533. [PMID: 31625613 DOI: 10.1111/pace.13820] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2019] [Revised: 10/03/2019] [Accepted: 10/15/2019] [Indexed: 11/30/2022]
Abstract
BACKGROUND Due to high failure rates, Medtronic withdrew the Sprint Fidelis lead (SFL) from the market. Passive fixation lead models exhibited better survival than active models, but most studies have limited follow-up. Aim of this study was to give insights into passive lead survival with a follow-up of 10 years. METHODS In two large Swiss centers, patients with passive SFLs were identified and data from routine implantable cardioverter defibrillator (ICD) follow-ups were collected. Patients were censored at time of death, last device interrogation (if lost to follow-up), time of lead revision (in non-SFL-related problems), or at database closure (31th December 2017). We defined lead failure as any of the following: lead fracture with inappropriate discharge; sudden increase in low-voltage impedance to >1500 or high-voltage impedance to >100 Ω; >300 nonphysiological short VV-intervals. RESULTS We identified 145 patients. Age at implant was 60 ± 12 years with a median follow-up of 10.2 (interquartile range [IQR]: 5.0-11.2) years. Thirty-five percent of patients died after 5.4 ± 2.7 years. A total of 19 leads (13%) failed after 6.7 ± 3.2 years (range: 1.2-12.0). Overt malfunction with shocks existed in four patients (3%). Cumulative lead survival was 93.1% at 6, 88.2% at 8, 83.8% at 10, and 77.6% at 11 years, respectively, with 35% of implanted leads under monitoring at 10 years. Lead survival fits best a Weibull distribution with accelerating failure rates (k = 1.95, 95% CI 1.32-2.87, P < 0.001). CONCLUSIONS During very long-term follow-up, failure rate of the passive SFL shows an increase resulting in an impaired lead survival of 84% at 10 years.
Collapse
Affiliation(s)
- Simon Martin Frey
- Department of Cardiology, University Hospital of Basel, Basel, Switzerland
| | | | - David Altmann
- Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | - Roman Brenner
- Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | - Michael Kühne
- Department of Cardiology, University Hospital of Basel, Basel, Switzerland
| | - Peter Ammann
- Department of Cardiology, Kantonsspital St. Gallen, St. Gallen, Switzerland
| | - Michael Coslovsky
- Department of Cardiology, University Hospital of Basel, Basel, Switzerland
| | - Stefan Osswald
- Department of Cardiology, University Hospital of Basel, Basel, Switzerland
| | - Beat Schaer
- Department of Cardiology, University Hospital of Basel, Basel, Switzerland
| |
Collapse
|
5
|
Palmisano P, Pisanò EC, La Rosa C, Ammendola E, Zaccaria M, Milanese G, Lauretti M, Rillo M, Aloisio A, Rago A, Nigro G, Accogli M. Effectiveness of Implantable DEfibrillators Alert Systems. J Cardiovasc Med (Hagerstown) 2019; 20:114-121. [DOI: 10.2459/jcm.0000000000000745] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Kruppa J, Lepenies B, Jung K. A genetic algorithm for simulating correlated binary data from biomedical research. Comput Biol Med 2017; 92:1-8. [PMID: 29132014 DOI: 10.1016/j.compbiomed.2017.10.023] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/04/2017] [Revised: 10/20/2017] [Accepted: 10/20/2017] [Indexed: 12/01/2022]
Abstract
Correlated binary data arise in a large variety of biomedical research. In order to evaluate methods for their analysis, computer simulations of such data are often required. Existing methods can often not cover the full range of possible correlations between the variables or are not available as implemented software. We propose a genetic algorithm that approaches the desired correlation structure under a given marginal distribution. The procedure generates a large representative matrix from which the probabilities of individual observations can be derived or from which samples can be drawn directly. Our genetic algorithm is evaluated under different specified marginal frequencies and correlation structures, and is compared against two existing approaches. The evaluation checks the speed and precision of the approach as well as its suitability for generating also high-dimensional data. In an example of high-throughput glycan array data, we demonstrate the usability of our approach to simulate the power of global test procedures. An implementation of our own and two other methods were added to the R-package 'RepeatedHighDim'. The presented algorithm is not restricted to certain correlation structures. In contrast to existing methods it is also evaluated for high-dimensional data.
Collapse
Affiliation(s)
- Jochen Kruppa
- Institute for Animal Breeding and Genetics, University of Veterinary Medicine Hannover, Hannover, Germany
| | - Bernd Lepenies
- Immunology Unit, University of Veterinary Medicine Hannover, Hannover, Germany; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover, Germany
| | - Klaus Jung
- Institute for Animal Breeding and Genetics, University of Veterinary Medicine Hannover, Hannover, Germany; Research Center for Emerging Infections and Zoonoses (RIZ), University of Veterinary Medicine Hannover, Hannover, Germany.
| |
Collapse
|
7
|
Providência R, Kramer DB, Pimenta D, Babu GG, Hatfield LA, Ioannou A, Novak J, Hauser RG, Lambiase PD. Transvenous Implantable Cardioverter-Defibrillator (ICD) Lead Performance: A Meta-Analysis of Observational Studies. J Am Heart Assoc 2015; 4:e002418. [PMID: 26518666 PMCID: PMC4845221 DOI: 10.1161/jaha.115.002418] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2015] [Accepted: 08/19/2015] [Indexed: 11/16/2022]
Abstract
BACKGROUND Despite the widespread use of implantable cardioverter-defibrillators (ICDs) in clinical practice, concerns exist regarding ICD lead durability. The performance of specific lead designs and factors determining this in large populations need clarification. METHODS AND RESULTS The Medline, Embase, and Cochrane Collaboration databases were searched for studies including ≥2 of the most commonly implanted leads. The Mantel-Haenszel random-effects model was used. Seventeen studies were selected, including a total of 49 871 patients-5538 implanted with Durata (St. Jude Medical Inc), 10 605 with Endotak Reliance (Boston Scientific), 16 119 with Sprint Quattro (Medtronic Corp), 11 709 with Sprint Fidelis (Medtronic Corp), and 5900 with Riata (St. Jude Medical Inc)-with follow-up of 136 509 lead-years. Although the Durata lead presented a numerically higher rate, no statistically significant differences in the mean incidence of lead failure (0.29%-0.45% per year) were observed in comparison of the 3 nonrecalled leads. A higher event rate was documented with the Riata (1.0% per-year increase) and Sprint Fidelis (>2.0% per-year increase) leads compared with nonrecalled leads. An indication of increased incidence of Durata lead failure versus Sprint Quattro and Endotak Reliance leads was observed in 1 of 3 included studies, allowing for comparison of purely electrical lead failure, but this requires further evaluation. CONCLUSIONS Endotak Reliance (8F), Sprint Quattro (8F), and Durata (7F) leads displayed low annual incidence of failure; however, long-term follow-up data are still scarce. More data are needed to clarify the performance and safety of the Durata lead.
Collapse
Affiliation(s)
- Rui Providência
- The Heart HospitalUniversity College of London Hospitals NHS TrustLondonUnited Kingdom
- Barts Heart CentreBarts Health NHS TrustLondonUnited Kingdom
| | - Daniel B. Kramer
- Cardiac ElectrophysiologyBeth Israel Deaconess Medical CenterHarvard Medical SchoolBostonMA
| | - Dominic Pimenta
- University College of London Hospitals NHS TrustLondonUnited Kingdom
| | - Girish G. Babu
- The Heart HospitalUniversity College of London Hospitals NHS TrustLondonUnited Kingdom
| | | | | | - Jan Novak
- Solothurner Spitaeler AGSolothurnSwitzerland
| | | | - Pier D. Lambiase
- The Heart HospitalUniversity College of London Hospitals NHS TrustLondonUnited Kingdom
- University College of LondonUnited Kingdom
- Barts Heart CentreBarts Health NHS TrustLondonUnited Kingdom
| |
Collapse
|
8
|
Piot O, Deballon R, Nitu D, Marquié C, da Costa A, Leclercq C, Defaye P, Sadoul N. Factors predicting Sprint Fidelis lead fracture: Results at 5years from a French multicentre registry. Arch Cardiovasc Dis 2015; 108:220-6. [DOI: 10.1016/j.acvd.2014.11.006] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/05/2014] [Revised: 11/01/2014] [Accepted: 11/04/2014] [Indexed: 11/16/2022]
|
9
|
Frey SM, Sticherling C, Kraus R, Ammann P, Kühne M, Osswald S, Schaer B. Very late follow-up of a passive defibrillator lead under recall: do failure rates increase during long-term observation. PACING AND CLINICAL ELECTROPHYSIOLOGY: PACE 2015; 38:306-10. [PMID: 25599764 DOI: 10.1111/pace.12578] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/11/2014] [Revised: 11/21/2014] [Accepted: 12/07/2014] [Indexed: 11/29/2022]
Abstract
BACKGROUND The Medtronic Sprint Fidelis lead (SFL; Medtronic Inc., Minneapolis, MN, USA) has a significantly impaired long-term survival, and active fixation leads fare worse than passive leads. The goal of this study was to present data of a series of passive SFL only with very long mean follow-up of more than 6 years. METHODS Patients in whom a passive SFL was implanted in two large Swiss centers were followed. We excluded eight (5.5%) patients with a follow-up of <6 months. Patients who died or were lost during follow-up were censored at death or last device check, all others on January 31, 2014. We employed two different definitions of failure: strict = fracture with inappropriate discharge; sudden increase in impedance >1,500 or high-voltage impedance >100 Ohm; >300 nonphysiological short interventricular-intervals. Lenient = any of the above plus a linear increase in impedance >1,500 Ohm or a linear decrease in sensing to a level that treating cardiologists considered inappropriate. RESULTS We included 137 patients. Age was 60 ± 12 years. Mean and median follow-up were 6.2 ± 2.1 and 6.8 (interquartile range 4.8-7.8) years. Applying the strict definition, 12 leads (8.8%) were replaced after 4.9 ± 2.4 years (range 1.2-8.1). Applying the lenient definition, 14 leads (10.2%) failed. Cumulative lead survival was 98.5% at 3, 96.9% at 4, 94.2% at 5, and 93.1% at 6 years. Leads "at risk" were: n = 122 (89%), 115 (84%), 101 (74%), and 88 (64%). CONCLUSIONS In this population with passive SFLs, 5-year lead survival is impaired with 94.2% based on 74% of leads "at risk" at this time point.
Collapse
|
10
|
Grazia Bongiorni M, Dagres N, Estner H, Pison L, Todd D, Blomstrom-Lundqvist C. Management of malfunctioning and recalled pacemaker and defibrillator leads: results of the European Heart Rhythm Association survey. Europace 2014; 16:1674-8. [DOI: 10.1093/europace/euu302] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
|